Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
21 May, 2019 17:02 IST
Cipla gets final nod for Tadalafil tablets
Source: IRIS | 07 Feb, 2019, 10.22AM
Comments  |  Post Comment

Cipla today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Tadalafil Tablets 20mg from the United States Food and Drug Administration (US FDA).

Cipla's Tadalafil Tablets 20mg is AB-rated generic therapeutic equivalent version of Eli Lilly & Co.'s Adcirca. It is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability.

According to IQVIA (IMS Health), Adcirca and its generic equivalents had US sales of approximately USD 490M for the 12-month period ending November 2018. The product is available for shipping immediately.

Shares of the company gained Rs 11.2, or 2.12%, to trade at Rs 539.15. The total volume of shares traded was 25,208 at the BSE (9.22 a.m., Thursday).



Cipla Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer